#1 Clinical Trials Search in Europe

ALLERGEN EXTRACTS

Clinical trials are studying LEPIDOGLYPHUS DESTRUCTOR, POLYMERISED EXTRACT in people with dust mite and Lepidoglyphus destructor allergy. These studies look at whether the treatment is safe and effective for allergic rhinitis, rhinoconjunctivitis, and some mild-to-moderate controlled asthma. The main target group is adolescents and adults aged 12 to 65 years.

Table of contents

Trial overview

The available study is an interventional clinical trial, which means researchers give a treatment and then measure the results.[1] It is testing LEPIDOGLYPHUS DESTRUCTOR, POLYMERISED EXTRACT for people with allergy related to dust mite and Lepidoglyphus destructor.[1]

The trial is designed to assess both efficacy and safety, with efficacy meaning how well the treatment works in real participants.[1] The study is in Phase 3, which is a later stage of testing in a larger group of people.[1]

Who can join the study

The study includes participants aged 12 to 65 years.[1] It focuses on people with moderate-to-severe persistent allergic rhinitis or rhinoconjunctivitis.[1]

Some participants may also have mild-to-moderate controlled allergic asthma.[1] In simple terms, this means the asthma is present but is stable and not severe at the time of the study.[1]

Treatment and comparison

The trial compares the active study product with a placebo, which looks the same but does not contain active ingredients.[1] The active product is given as a suspension for injection under the skin.[1]

This design helps researchers see whether any improvement is due to the study treatment and not to chance or expectation alone.[1]

Outcomes being measured

The main outcome is the Rhinoconjunctivitis Combined Symptom and Medication Score, also called RCSMS.[1] This score combines two important parts: how bad the allergy symptoms are and how much allergy medicine the participant needs.[1]

The score is measured over 4 weeks after one year of treatment, and it is recorded in the participant diary.[1] This helps researchers understand the treatment effect over time in daily life.[1]

Trial status and size

The study status is Authorised.[1] The planned enrollment is 120 participants, which means the trial is set up to include 120 people.[1]

Because the trial is relatively small compared with many late-stage studies, each participant’s data will be important for understanding the results.[1]

What this means for patients

For patients, this study is looking at whether LEPIDOGLYPHUS DESTRUCTOR, POLYMERISED EXTRACT can help reduce allergy symptoms in people with dust mite and Lepidoglyphus destructor allergy.[1] The trial is especially relevant for people who have ongoing nose and eye allergy symptoms, with or without stable asthma.[1]

The most important question in the study is whether the treatment can improve daily symptoms and lower the need for allergy medicine over time.[1]

Trial ID Phase Condition studied Status Enrollment
2025-522771-28-00 Phase 3 Moderate-to-severe allergic rhinitis/rhinoconjunctivitis with or without mild-to-moderate controlled allergic asthma Authorised 120

FAQ

  • What is being studied in trials of LEPIDOGLYPHUS DESTRUCTOR, POLYMERISED EXTRACT? The trial is studying whether this treatment can improve allergy symptoms and reduce the need for medicine. It compares the active treatment with a placebo, which looks the same but has no active ingredients.
  • Who can take part in the trial? The study includes people aged 12 to 65 years. They must have moderate-to-severe allergic rhinitis or rhinoconjunctivitis, with or without mild-to-moderate controlled asthma.
  • What phase is the trial? This is a Phase 3 trial. Phase 3 studies usually test how well a treatment works in a larger group of people and continue to check safety.
  • What condition is the trial focused on? The trial focuses on allergy caused by dust mites and Lepidoglyphus destructor. It is aimed at people with persistent nasal and eye allergy symptoms, sometimes together with controlled asthma.
  • What outcome is the trial measuring? The main outcome is the Rhinoconjunctivitis Combined Symptom and Medication Score, or RCSMS. This score measures both symptoms and the use of allergy medicine over 4 weeks after one year of treatment.

Ongoing Clinical Trials on ALLERGEN EXTRACTS

  • Dermatophagoides farinae, Dermatophagoides pteronyssinus, and Lepidoglyphus destructor Immunotherapy for Allergic Rhinitis and Rhinoconjunctivitis in Patients With or Without Mild Asthma

    Not yet recruiting

    3 1
    Investigated drugs:
    Spain

Glossary

  • Allergic rhinitis: A long-lasting allergy that causes a runny nose, blocked nose, sneezing, or itching.
  • Rhinoconjunctivitis: Allergy symptoms that affect both the nose and the eyes.
  • Asthma: A condition that makes the airways in the lungs narrow and swell, causing breathing problems.
  • Controlled asthma: Asthma that is being kept stable and not causing major symptoms.
  • Placebo: A treatment that looks like the real one but has no active ingredient. It helps researchers compare results fairly.
  • Phase 3: A later stage of clinical testing done in a larger group of people to see how well a treatment works and to monitor safety.
  • Interventional study: A study where researchers give a treatment and then measure the effects.
  • Subcutaneous: Given as an injection under the skin.
  • Primary outcome: The main result the trial is designed to measure.
  • RCSMS: Short for Rhinoconjunctivitis Combined Symptom and Medication Score. It combines symptom levels and medicine use into one score.

References

  1. https://clinicaltrials.gov/study/2025-522771-28-00